Search clinical trials for: AGN-229666

Total 2529 results

Allergan

Completed

AGN-229666 for the Treatment of Allergic Conjunctivitis

Allergic Conjunctivitis

Japan
Allergan

Completed

AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

Conjunctivitis, Allergic

Japan
Allergan

Completed

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

Conjunctivitis, Allergic

Japan
Ahn-Gook Pharmaceuticals Co.,Ltd

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute Bronchitis

Acute Bronchitis

Korea, Republic of
Allgenesis Biotherapeutics Inc.
ORA, Inc.

Completed

A Study of AG-80308 in Dry Eye Patients

Dry Eye Disease

United States
Allergan

Completed

A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

United States
Allergan

Completed

AGN-199201 for the Treatment of Erythema With Rosacea

Erythema | Rosacea

United States
Allergan

Completed

A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects

Healthy Volunteers

United States
Allergan

Completed

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

Erythema | Rosacea

United States
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Allergan

Completed

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

Urinary Bladder, Overactive

France, United States, Netherlands
Allergan

Completed

A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

Presbyopia

United States
Allergan

Terminated

A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia

Neuralgia, Postherpetic

United States, Austria, Poland, Germany
Allergan

Completed

Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Erythema | Rosacea

United States
Allergan

Completed

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

Neuralgia, Postherpetic

Poland, United States, Czech Republic, Germany
Allergan

Completed

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

Presbyopia

United States
Allergan

Completed

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

Dry Eye Syndrome | Dry Eye Disease

United States
Jeil Pharmaceutical Co., Ltd.

Recruiting

Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 in Healthy Subjects

Diabetes Mellitus

France
Allergan

Completed

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Allergan

Completed

A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

Presbyopia

United States
Allergan

Completed

Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

Dry Eye Syndromes | Healthy Volunteers

United States
Allergan

Completed

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States, Puerto Rico
Allergan

Terminated

Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

Cystitis, Interstitial

United States
Gordon Schanzlin New Vision
AbbVie

Withdrawn

Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses

Presbyopia
International Centre for Diarrhoeal Disease Research...
University of California, Davis

Completed

Breast Milk Zinc Transfer to Appropriate- and Small-for-gestational-age Bangladeshi Infants

Small for Gestational Age at Delivery | Post-term Infant, Not Heavy-for-dates

Bangladesh
AbbVie

Recruiting

A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines

Glabellar Lines

China, Taiwan
Gate Neurosciences, Inc

Completed

AGN-241751 in the Treatment of Major Depressive Disorder

Major Depressive Disorder

United States
Allergan

Completed

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States, Canada, Germany, Hungary, Poland
Vitae Pharmaceuticals, Inc.

Terminated

AGN-242428 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Allergan

Terminated

Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome

Fibromyalgia

Switzerland, United States, United Kingdom
AbbVie

Completed

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

Japan
Gate Neurosciences, Inc

Completed

AGN-241751 in the Treatment of Major Depressive Disorder

Depressive Disorder, Major

United States
Allergan

Terminated

Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Dry Eye Syndromes

United States
Allergan

Terminated

Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Dry Eye Syndromes

Taiwan, United States, Czechia, Poland, Philippines, Turkey, France, Germany, Hungary, Italy, Spain, United Kingdom
Allergan

Terminated

Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain

Irritable Bowel Syndrome

United States
Allergan

Completed

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines

Glabellar Lines

United States, Canada
AbbVie

Enrolling by invitation

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine

Episodic Migraine

United States, Canada, Denmark, Hungary, Italy, Poland, Puerto Rico, Spain, United Kingdom, Israel, Japan, Sweden
Allergan

Completed

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

Diabetic Neuropathy, Painful

United States
Allergan

Completed

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD

Macular Degeneration

United States
Allergan

Completed

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease

Dry Eye Syndromes

United States
Allergan

Completed

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Migraine, With or Without Aura

United States
AbbVie

Active, not recruiting

A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth

Perioral Lines

China
AbbVie

Not yet recruiting

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Hypothyroidism
AbbVie

Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine (Kaleidoscope)

Episodic Migraine

United States, Puerto Rico, Hungary, Spain, Canada, Netherlands, Israel, Sweden, Poland, France, Denmark, Japan, United Kingdom, Italy, Romania, Belgium
AbbVie

Active, not recruiting

A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE™ Gel Filler for Change in Neck Lines in Adult Chinese Participants

Neck Lines

China
AbbVie

Completed

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

Post-Operative Atrial Fibrillation

United States, Austria, Canada, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom
Allergan

Completed

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Ocular Hypertension | Glaucoma, Open-Angle

United States
Allergan

Completed

A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age (TAURUS)

Presbyopia

Australia

3

Subscribe